Medisca Signs Deal as Exclusive Global Distributor outside the USA & Israel for the Padagis Line of ORA Products
12.1.2022 09:00:00 EET | Business Wire | Press release
On December 9, 2021, Medisca entered into an exclusive global manufacture, supply, license and distribution agreement with Padagis (formerly, the Rx Division of Perrigo) for their ORA Product Line consisting of the following Padagis products in finished form: ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend®, and ORA-Blend® SF. With this, Medisca has exclusive distribution rights on all global markets except the United States and Israel, and non-exclusive distribution rights with contractual benefits in Australia.
“This exclusive agreement reinforces Medisca’s commitment as a pioneer in personalized medicine around the world,” says Panagiota Danopoulos, Senior Vice President Global Strategy & Innovation, Medisca. “Partnering with Padagis is another important step in expanding our reach, as we continue to build the power of Medisca brands into a global trailblazer across the pharmaceutical compounding, scientific lab, cosmetic, and other healthcare industries.”
Developed over 20 years ago by Paddock Laboratories, which was acquired by Perrigo in 2011, ORA products are manufactured by Padagis in Minnesota and are the longest-standing compounding oral vehicles on the market, with over 150 stability studies to support their use. In fact, this unmatched study portfolio is key to why many view ORA products as the go-to compounding oral vehicles across the globe. Outside of compounding, the ORA brand continues to make its mark, found in department stores as over the counter products and included as part of FDA-approved finished drugs.
“Until now, the ORA Product Line has used multiple distributors worldwide,” says Colter VanStedum, Executive Vice President and Chief Growth Officer, Padagis. “Our decision to centralize distribution through Medisca was heavily influenced by their global distribution capabilities. The ORA products have vast potential in critical patient care – especially pediatric care – and should be widely available to pharmacists, physicians, and most importantly, patients – in all markets across the globe. Creating this partnership was a strategic move to maximize positive impact to patients around the world.”
Danopoulos adds, “Medisca’s quality standard and international network are what allow an agreement like this to be signed. It is another key milestone in our commitment to growth and leadership, making a meaningful, sustainable difference in emerging markets.”
With this agreement, Medisca will also be filing international trademark applications in certain countries in its name.
About MEDISCA
MEDISCA is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For 30+ years, MEDISCA has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, MEDISCA provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information about MEDISCA, please visit www.medisca.com, and follow us on Twitter at @medisca.
About PADAGIS
PADAGIS is dedicated to improving the well-being of as many patients and consumers as possible by developing, manufacturing and distributing high quality, affordable specialized healthcare products. The company is a leading provider of extended topical and other specialty pharmaceuticals, employing over 1,300 people worldwide. Visit PADAGIS online at (http://www.padagis.com).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005211/en/
Contact information
Panagiota Danopoulos
SVP Global Strategy & Innovation at Medisca
www.medisca.ca
1-800-665-6334
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 20:16:00 EEST | Press release
Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build
Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 19:16:00 EEST | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure controlsoftware to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers. The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses. The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly fas
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 11:52:00 EEST | Press release
SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 08:10:00 EEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom